Roche Is Discussing Lamifiban Submission Based On Troponin T Substudy
Executive Summary
Roche is in discussions with regulatory authorities regarding an indication for its intravenous glycoprotein IIb/IIIa platelet aggregation inhibitor lamifiban, based on a prospective substudy of its pivotal Phase III trial.
You may also be interested in...
Roche Likes Its Critical Mass But Could Amass More; $2 Bil. R&D Will Do
Roche's restructuring and internal growth obviates the need for a merger, even with the recent loss of several late-phase clinical projects, CEO Franz Humer told the Roche 1999 annual earnings conference March 30 in Basel.
Roche Likes Its Critical Mass But Could Amass More; $2 Bil. R&D Will Do
Roche's restructuring and internal growth obviates the need for a merger, even with the recent loss of several late-phase clinical projects, CEO Franz Humer told the Roche 1999 annual earnings conference March 30 in Basel.
Actelion bosentan
Roche no longer has right of first refusal for acquiring the endothelin antagonist from Actelion (1"The Pink Sheet" March 20, p. 16)